Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Xilio Therapeutics Inc
XLO
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$8.43
-0.11
-1.29%
Últ. Act.: Oct 19, 4:52 PM
$8.30
-0.24
-2.81%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Privacy Manager
Xilio Therapeutics Financials
Xilio Therapeutics (XLO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Xilio Therapeutics Q2 EPS $(0.33) Beats $(0.59) Estimate, Sales $18.692M Beat $12.720M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.59) by 44.07 percent. This is a 85.27 percent increase over losses of $(2.24) per share
Benzinga Newsdesk
PRO
Xilio Therapeutics Q1 EPS $(0.58) Beats $(0.66) Estimate, Sales $12.648M Beat $8.520M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.66) by 12.12 percent. This is a 76.71 percent increase over losses of $(2.49) per share from
Benzinga Newsdesk
PRO
Xilio Therapeutics Q4 EPS $0.81 Beats $(0.12) Estimate, Sales $13.686M Beat $7.960M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $(0.12) by 775 percent. This is a 128.93 percent increase over losses of $(2.80) per share from
Benzinga Newsdesk
PRO
Xilio Therapeutics Q3 EPS $(0.11) Misses $(0.03) Estimate, Sales $19.066M Beat $18.635M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.03) by 266.67 percent. This is a 50 percent increase over losses of $(0.22) per share from
Benzinga Newsdesk
PRO
Xilio Therapeutics Q2 EPS $(0.16) Misses $(0.08) Estimate, Sales $8.084M Miss $8.210M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 100 percent. This is a 33.33 percent increase over losses of $(0.24) per share from
Benzinga Newsdesk
Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings
Avi Kapoor
